Kari Williams, APRN
Nurse Practitioner · Cleveland, TNNPI 1467418095
Payments from drug & device makers
Across 676 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Johnson & Johnson$1K
- Takeda Pharmaceuticals U.S.A., Inc.$913
- Aimmune Therapeutics, Inc.$398
- Ardelyx, Inc.$396
- plus $3K from 27 others
What the payments were for
- Food & beverage$11,36799%
- Education$1321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 192 | $3,608 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 137 | $1,749 |
| Johnson & Johnson | 71 | $1,197 |
| Takeda Pharmaceuticals U.S.A., Inc. | 63 | $913 |
| Aimmune Therapeutics, Inc. | 18 | $398 |
| Ardelyx, Inc. | 24 | $396 |
| Gilead | 17 | $375 |
| Regeneron Healthcare Solutions, Inc. | 18 | $355 |
| Pfizer | 18 | $305 |
| Redhill Biopharma Inc. | 12 | $261 |
| Merck | 11 | $237 |
| Madrigal Pharmaceuticals | 9 | $229 |
| Ironwood Pharmaceuticals, Inc | 14 | $219 |
| Nestle Healthcare Nutrition Inc. | 13 | $208 |
| Phathom Pharmaceuticals, Inc. | 12 | $174 |
| Janssen Scientific Affairs, LLC | 1 | $110 |
| Evoke Pharma, Inc. | 7 | $103 |
| Novo Nordisk | 4 | $83 |
| QOL Medical, LLC | 4 | $66 |
| Daiichi Sankyo Inc. | 3 | $66 |
| Ipsen Biopharmaceuticals, Inc | 3 | $55 |
| Ferring Pharmaceuticals Inc. | 4 | $54 |
| Fresenius Kabi USA, LLC | 2 | $43 |
| Bristol Myers Squibb | 3 | $42 |
| Intra-sana Laboratories | 3 | $39 |
| Lilly USA, LLC | 2 | $38 |
| Alnylam Pharmaceuticals Inc. | 2 | $34 |
| Amgen | 2 | $33 |
| Celltrion USA Inc. | 2 | $33 |
| Medtronic | 2 | $28 |
| Boehringer Ingelheim | 1 | $25 |
| Intercept Pharmaceuticals, Inc. | 1 | $16 |
| Organon | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,499 in reported general payments places this provider in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 51 | $157,940 |
| ZenpepLipase/Protease/Amylase | 19 | $103,525 |
| RezdiffraResmetirom | 13 | $61,318 |
| CreonLipase/Protease/Amylase | 18 | $54,843 |
| LinzessLinaclotide | 63 | $44,684 |
| Ursodiol | 44 | $31,610 |
| IbsrelaTenapanor Hcl | 16 | $26,576 |
| MovantikNaloxegol Oxalate | 14 | $7,773 |
| Famotidine | 436 | $6,385 |
| Lubiprostone | 22 | $5,630 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 94 | $5,542 |
| Pantoprazole Sodium | 316 | $3,556 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 20 | $3,364 |
| Ondansetron OdtOndansetron | 105 | $3,288 |
| Colestipol Hcl | 28 | $2,714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,749 | $157,94051 claims |
| Aimmune Therapeutics, Inc.Zenpep | $398 | $103,52519 claims |
| AbbVieCreon, Linzess | $3,608 | $99,52881 claims |
| Madrigal PharmaceuticalsRezdiffra | $229 | $61,31813 claims |
| Ardelyx, Inc.Ibsrela | $396 | $26,57616 claims |
| Redhill Biopharma Inc.Movantik | $261 | $7,77314 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $54 | $3,36420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.
Other nurse practitioner in Cleveland
- Amy HatcherMurfreesboro$1.1M
- Karen RodenKnoxville$265K
- Susan UtleyNashville$194K
- Whitney EricksonMemphis$159K
- Erica HembreeKnoxville$125K
- Brooke FaughtNashville$89K
- Lauren WelchNashville$71K
- Cara StoutKingsport$71K
- S Marie HamiltonOoltewah$64K
- Cynthia WilsonChattanooga$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.